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Abstract 
Antiepileptogenic agents that prevent the development of epilepsy following a brain insult remain 
the holy grail of epilepsy therapeutics. We have employed a label-free proteomic approach that 
allows quantification of large numbers of brain-expressed proteins in a single analysis in the mouse 
(male C57BL/6J) kainate (KA) model of epileptogenesis. In addition, we have incorporated two 
putative antiepileptogenic drugs, post-synaptic density protein-95 blocking peptide (PSD95BP or Tat-
NR2B9c) and a highly selective inducible nitric oxide synthase inhibitor, 1400W, to give an insight 
into how such agents might ameliorate epileptogenesis. The test drugs were administered after 
induction of status epilepticus (SE) and animals were euthanized at 7 days, their hippocampi 
removed, and subjected to LC-MS/MS analysis. A total of 2,579 proteins were identified; their 
normalized abundance was compared between treatment groups using ANOVA, with correction for 
multiple testing by false discovery rate. Significantly altered proteins were subjected to gene 
ontology and KEGG pathway enrichment analyses. KA-induced SE was most robustly associated with 
an alteration in the abundance of proteins involved in neuroinflammation, including heat shock 
protein beta-1 (HSP27), glial fibrillary acidic protein, and CD44 antigen. Treatment with PSD95BP or 
1400W moderated the abundance of several of these proteins plus that of secretogranin and Src 
substrate cortactin. Pathway analysis identified the glutamatergic synapse as a key target for both 
drugs. Our observations require validation in a larger-scale investigation, with candidate proteins 
explored in more detail. Nevertheless, this study has identified several mechanisms by which 
epilepsy might develop and several targets for novel drug development. 
Keywords 
Neuroinflammation, inducible nitric oxide synthase (iNOS), post-synaptic density, glutamatergic 
synapse, disease modification. 
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Significance statement 
Understanding the mechanisms that underlie the development of epilepsy has the potential to 
identify targets for antiepileptogenic agents that might prevent, delay or reverse the onset of 
spontaneous seizures. We have used the mouse kainate model of epileptogenesis and label-free 
proteomics to explore the effects of two mechanistically distinct, putative antiepileptogenic drugs. 
Our data support the contribution of neuroinflammation to epileptogenesis and its amelioration by 
drugs that target the glutamatergic synapse. Our findings offer unbiased insights into the events that 
occur during epileptogenesis and act as an important proof of concept for future, larger scale 
studies. 
 
 
 
Graphical abstract and hypothesis 
Kainate (KA)-induced status epilepticus hyperexcites neurons and activates ionotropic glutamate 
receptors, including NMDAR, AMPAR, and GluR6 (Bernard et al., 1999; Schauwecker, 2010; Staley et 
al., 2011). These receptors physically interact with post-synaptic density protein 95 (PSD95) which 
acts as a scaffolding protein at the postsynaptic membrane (Wyneken et al., 2001; Swann et al., 
2007; Savinainen et al., 2001). PSD95 activation and its interaction with NMDARs are mediated by 
Src kinases* which drive hyperexcitability and neurodegeneration (Ali and Salter, 2001). 
Hyperexcited neurons activate both microglia and astrocytes to induce the expression of inducible 
nitric oxide synthase (iNOS)* and Src kinase* (Cosgrave et al., 2008; Sharma et al., 2018; Putra et al., 
2019). The products of these enzymes, and many other proteins, exacerbate hyperexcitability and 
activate neuroinflammation and neurodegeneration pathways. Thus, the hypothesis is that PSD95 
blocking peptide (PSD95BP; Tat-NR2B9c) and the iNOS inhibitor 1400W will impact KA-induced 
changes. *Note: The starred proteins were not detected in the present study. 
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1. Introduction 
Epileptogenesis is the process of developing epilepsy in response to altered gene expression or 
exposure to neurotoxins or head trauma (Pitkänen et al., 2015; Russo and Citraro, 2018). 
Epileptogenesis in humans and animal models have common features such as neuroinflammation, 
neurodegeneration, synaptic re-organization, and cognitive impairment (Beach et al., 1995; 
Schmeiser et al., 2017; Koepp et al., 2017; Leal et al., 2017; Walker et al., 2017; Papageorgiou et al., 
2018; Koh, 2018). We have previously demonstrated some of these in both rat and mouse models of 
kainate (KA)-induced temporal lobe epilepsy (TLE) (Puttachary et al., 2016a; Puttachary et al., 
2016b).  
 
In experimental models, chemoconvulsants such as the glutamate analog KA or the 
parasympathomimetic pilocarpine are commonly used to induce status epilepticus (SE). These 
models of TLE are well characterized, especially in rats with respect to gliosis, neurodegeneration, 
and spontaneous recurrent seizures (SRS). KA-induced SE in C57BL/6J (C57) mice triggers 
epileptogenesis but is rarely used as a TLE model for chronic studies due to infrequent SRS and 
insufficient evidence for all classical features of epileptogenesis. In our studies, continuous video-
EEG recording for four months post-SE in C57 mice revealed a high frequency of convulsive SRS 
during the first 4-6 weeks post-SE, with electrographic non-convulsive seizures (NCS) persisting 
throughout (Puttachary et al., 2015). Immunohistochemistry (IHC) at 7, 14 and 28 days post-SE 
revealed significant gliosis, neurogenesis, and neurodegeneration in the hippocampus. In the current 
study, we chose 7 days post-SE, the maximum brain injury time-point in C57 mice (Puttachary et al., 
2016a), to identify changes in protein expression in the hippocampus during epileptogenesis. We 
have used a label-free proteomics approach for this purpose. We have simultaneously investigated 
the effects of two mechanistically distinct putative antiepileptogenic agents; a highly selective 
inducible nitric oxide (NO) synthase (iNOS) inhibitor, 1400W, to target glial-derived NO and a post-
synaptic density protein 95 (PSD95) blocking peptide (PSD95BP, also known as Tat-NR2B9c) to target 
neuronal hyperexcitability. 
 
Our previous studies, and those of others, have shown that iNOS expression in hippocampus 
increases by 24 to 72 hours post-SE and persists for a long period (Cosgrave et al., 2008; Vezzani et 
al., 2013; Putra et al., 2019). Therefore, we hypothesized that iNOS is a potential promoter of 
epileptogenesis. Our studies in rats have also demonstrated that 1400W, when administered soon 
after KA-induced SE, significantly reduced neuroinflammation and epileptogenesis and also reduced 
neuropathic pain following nerve injury (Puttachary et al., 2016b; Staunton et al., 2018), suggesting 
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its role in dampening neuronal hyperexcitability. In a recent organophosphate (OP) toxicity study, we 
showed that 1400W could suppress OP-induced upregulation of iNOS, 3-nitrotyrosine, gliosis, pro-
inflammatory cytokines/chemokines, neurodegeneration, and SRS (Putra et al., 2019). While iNOS is 
predominantly expressed in glial cells in the CNS, PSD95 is localized to the post-synaptic neuronal 
cell membrane. PSD95 is a scaffolding protein and a potential target for post-synaptic modification 
(Wyneken et al., 2001; Swann et al., 2007). It is implicated in synaptic maturation and strengthening, 
and in plasticity, through its modulation of ionotropic glutamate receptors. Uncoupling of PSD95 
from the NR2B subunit of the NMDA receptor disengages the intracellular cascade, affords 
neuroprotection in both pilocarpine-induced SE (Dykstra et al., 2009) and cerebral ischemia models 
(Aarts et al., 2002; Sun et al., 2008), and facilitates the isolation of excitotoxicity/neurodegeneration 
from epileptogenesis.  
 
In this study, we investigated the effects of KA-induced SE and of 1400W and PSD95BP, when given 
alone and subsequent to SE, on the hippocampal proteomic profile in C57 mice at 7 days post-SE. 
Proteins whose expression was significantly altered in comparisons between treatment groups are 
reported and their potential contributions to epileptogenesis discussed.  
 
2. Materials and methods 
2.1 Animals 
Adult male C57BL/6J mice (25-30 g) were purchased from Charles River Laboratories, Margate, UK.  
All animals were housed under standard conditions in the Biomedical Services Unit, University of 
Liverpool, with 12 hour light/dark cycle and access to food and water ad libitum.  Animals were 
randomized and habituated in their housing environment in groups of five per cage for at least seven 
days before any experimental procedures were performed.  There were six treatment groups (n=4 
mice per group) as outlined in Figure 1. Full details of drug formulations and administration are 
provided in sections 2.2 and 2.3. All in vivo experimental procedures were carried out in accordance 
with the Animals (Scientific Procedures) Act, UK (1986). Where appropriate, experiments were 
designed and have been reported in accordance with the principles of the ARRIVE guidelines 
(Kilkenny et al., 2010).   
 
2.2 Induction of status epilepticus 
Prior to the induction of SE, animals were weighed and then randomly assigned to individual cages, 
where food and water was available ad libitum.  Animals were single-housed from the initiation of SE 
until the end of the experiment. The study employed behavioural indicators of seizure severity which 
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were scored using a modified Racine scale (Racine, 2002) as follows: Stage 1, animals displayed 
mouth and facial twitching; Stage 2, animals displayed head nodding with myoclonic twitching and 
tremor; Stage 3, animals displayed forelimb clonus with a lordotic posture and Straub tail; Stage 4, 
animals reared with concomitant forelimb clonus; Stage 5, animals experienced a generalized clonic 
convulsion with wild running or jumping (Hellier et al., 1998; Beamer et al., 2012; Schauwecker, 
2012; Macias et al., 2013; Puttachary et al., 2015). 
 
KA (Abcam, Cambridge, UK) was prepared fresh, as required, at a concentration of 2.5 mg/ml in 
sterile distilled water and sonicated for approximately 15 minutes until fully dissolved.  Mice 
assigned to initial treatment with KA (i.e. Groups 2, 4 and 6) received 5 mg/kg KA (i.p. in 50-60 μL) 
every 30 minutes until the onset of the first Stage 5 seizure, at which point KA administration was 
discontinued. The vast majority of the mice required 4 injections of KA and only two mice required 
five injections to reach stage 5 seizures. The two mice that received five injections did not show any 
convulsive seizures prior to the fifth dose. We have previously shown that this method of SE 
induction, with repeated low dose (RLD) of KA, produces convulsive seizures lasting for >30 minutes 
with minimal mortality during the 2 hours of SE (Tse et al., 2014; Puttachary et al., 2015; Sharma et 
al., 2018). The control animals (i.e. those in Groups 1, 3 and 5) received four injections (i.p.) of 50-60 
μL distilled water separated by 30 minutes each to simulate KA administration.  Two hours after the 
onset of the first Stage 5 seizure (or after the fourth injection of distilled water in control animals), 
all mice received 10 mg/kg diazepam in 50-60 µL (i.p.) to standardise the duration of KA-induced SE. 
Diazepam was obtained from Hameln Pharmaceuticals, Gloucester, UK by the Named Veterinary 
Surgeon, Biomedical Services Unit, University of Liverpool. We and others have previously shown 
that the use of diazepam at this dose and time-point (> 45 minutes of continuous SE) does not 
interfere with the subsequent onset of epileptogenesis or neuropathology (Ben-Ari et al., 1980; 
Aroniadou-Anderjaska et al., 2008; Beamer et al., 2012; Puttachary et al., 2015; Puttachary et al., 
2016a). After diazepam administration, mice were returned to their individual cages prior to further 
intervention. 
 
2.3 Drug treatments 
Mice in Groups 1 and 2 (n=4 per group) served as treatment controls for drug interventions (Figure 
1). Each animal received a single administration of 75 μl sterile saline (i.v.), the vehicle for PSD95BP, 
into the tail vein at one hour after diazepam treatment and two further injections (i.p.) of 125-150 µl 
sterile distilled water, the vehicle for 1400W, at 21 and 69 hours after diazepam. 
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PSD95BP (Tat-NR2B9c) was kindly provided by Professor Tymianski at the University of Toronto. It 
comprises nine C-terminal residues [KLSSIESDV] of the NR2B subunit of the NMDA subtype of 
glutamate receptor (NMDAR) conjugated to the cell membrane protein transduction domain of a 
human immunodeficiency virus type 1 Tat protein, which facilitates the blood-brain barrier 
permeability (Schwarze et al., 1999; Aarts et al., 2002; Cui et al., 2007; Sun et al., 2008; Forder and 
Tymianski, 2009; Cook et al., 2012). In this study, PSD95BP was prepared in sterile saline solution 
(0.9% NaCl) and administered as a single bolus dose of 7.6 mg/kg in 75 μL (i.v.) via the tail vein to a 
total of eight mice (i.e. all animals in Groups 3 and 4) at one hour after diazepam administration 
(Figure 1). In previous studies using rodent models, this dose has been shown to interact with the 
PDZ domain of PSD95 and neuronal nitric oxide synthase (nNOS), and to disengage the PSD95-nNOS 
complex from NMDAR without affecting NMDAR-mediated currents (Cui et al., 2007). 
 
1400W dihydrochloride (Tocris Bioscience, Bristol, UK) was prepared at a concentration of 4 mg/ml 
in sterile distilled water and administered to a total of eight mice (i.e. all animals in Groups 5 and 6) 
at a dose of 20 mg/kg (i.p.) at one hour after diazepam treatment. This was followed by two further 
administrations, again at a dose of 20 mg/kg in 125-150 μl (i.p.), at 21 and 69 hours thereafter (i.e. at 
24 and 72 hours after the onset of the first Stage 5 seizure; Figure 1). The dose and treatment 
schedule were chosen on the basis of our previous work on NO (and that of others) and modified for 
use in mice. It has been shown that KA-induced pro-inflammatory cytokines and NO occurs in phases 
after SE (Ravizza et al., 2005; Ryan et al., 2014). We had also observed a reduction in iNOS 
expression in glial cells and gliosis at 72 hours in the animals treated with NOS inhibitors, after 
induction of SE, in the rat and C57 mouse models (Cosgrave et al., 2008; Beamer et al., 2012). 
 
2.4 Tissue preparation 
Seven days after induction of SE, all mice were euthanized with an overdose of sodium 
pentobarbitone (Pentoject®; 60 mg/kg, i.p.) and death confirmed by exsanguination. Sodium 
pentobarbitone was obtained from Animalcare Limited (York, UK) by the Named Veterinary Surgeon, 
Biomedical Services Unit, University of Liverpool. Brains were rapidly removed post-mortem and the 
hippocampi dissected on ice and placed in chilled cryovials prior to being snap-frozen in liquid 
nitrogen. All tissue samples were coded and stored at -800C until required for proteomic analysis.  
 
2.5 Sample preparation for proteomic analysis 
All chemicals and solvents (HPLC grade) were obtained from Sigma Aldrich (Gillingham, UK) unless 
otherwise stated. Hippocampi were removed from storage, thawed on ice and homogenised directly 
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in the storage cryovial in 0.5 mL of ice-cold 25 mM NH4HCO3 for 30 seconds using a Tissue Ruptor 
(Qiagen, UK). A 15 µL aliquot of each homogenate (equal to 50-100 µg protein) was added to a low-
bind tube and diluted to 170 µL using 0.06% (w/v) Rapigest SF (Waters MS Technologies, 
Manchester, UK) in 25 mM NH4HCO3. Samples were stored at -20°C until all homogenisations were 
complete. Samples were then thawed, heated to 80°C for 10 minutes, reduced by the addition of 10 
µL of 60 mM dithiothreitol (Melford Laboratories, Ipswich, UK) in 25 mM NH4HCO3, and incubated at 
60°C for 10 minutes. Samples were subsequently alkylated by the addition of 10 µL of 180 mM 
iodoacetamide and incubated at room temperature in the dark for 30 minutes. Thereafter, 10 µL of 
0.2 µg/µL trypsin (in 50 mM acetic acid) was added and samples incubated overnight at 37°C with 
intermittent shaking. Following overnight incubation, the protein content of each sample was 
assayed using a modification of the Bradford assay (Bradford, 1976). Rapigest SF was then removed 
by the addition of 2 µL of 99% (v/v) trifluoroacetic acid and the samples incubated at 370C for 45 
minutes.  Samples were centrifuged at 17,200 x g for 30 minutes and supernatants transferred to 
fresh 0.5 mL low-bind tubes. The centrifugation step was repeated and 10 μL of the final supernatant 
was then transferred to a total recovery vial (Waters, UK) for proteomic analysis by liquid 
chromatography-mass spectrometry (LC-MS).   
 
2.6 Proteomic analysis 
All peptide separations were carried out using an Ultimate 3000 Nanosystem (Dionex/Thermo Fisher 
Scientific, UK). For each analysis, 1 µg (protein equivalent) of sample was loaded onto a trapping 
column (Acclaim PepMap 100, 2 cm x 75 µm inner diameter, C18, 3 µm, 100 Å) at 5 µL/min with an 
aqueous solution containing 0.1% (v/v) trifluoroacetic acid and 2% (v/v) acetonitrile. After 3 minutes, 
the trap column was set in-line with an analytical column (Easy-Spray PepMap® RSLC 50 cm x 75 µm 
inner diameter, C18, 2 µm, 100 Å) (Dionex, UK). Peptide elution was performed by applying a mixture 
of solvents A and B. Solvent A was HPLC grade water with 0.1% (v/v) formic acid, and solvent B was 
80% acetonitrile (v/v) with 0.1% (v/v) formic acid. Separations were performed by applying a linear 
gradient of 3.8% to 40% solvent B over 90 minutes at 300 nl/min followed by a washing step (5 
minutes at 99% solvent B) and an equilibration step (15 minutes at 3.8% solvent B).  
 
The Q Exactive instrument was operated in data dependent positive (ESI+) mode to automatically 
switch between full scan MS and MS/MS acquisition. Survey full scan MS spectra (m/z 300-2000) 
were acquired in the Orbitrap with 70,000 resolution (m/z 200) after accumulation of ions to 1x106 
target value based on predictive automatic gain control (AGC) values from the previous full scan. 
Dynamic exclusion was set to 20 seconds. The 10 most intense multiply charged ions (z ≥ 2) were 
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sequentially isolated and fragmented in the octopole collision cell by higher energy collisional 
dissociation (HCD) with a fixed injection time of 50 milliseconds and resolution of 17,500. Typical 
mass spectrometric conditions were as follows: spray voltage 2.1 kV, no sheath or auxillary gas flow; 
heated capillary temperature 250°C; normalised HCD collision energy 30%. The MS/MS ion selection 
threshold was set to 2 x 104 counts and a 2 m/z isolation width was set. 
 
2.7 Data analysis 
Raw data files were uploaded into Progenesis LC-MS version 3.0 (Nonlinear Dynamics Ltd, UK) for 
automatic alignment and peak picking. Data was filtered with peptide charges of +1 and >7 removed. 
The resulting peak list was submitted to the Mascot search engine (version 2.6; Matrix Science, UK) 
and searched against a reviewed Mouse UniProt protein database (date: 15/02/17; containing 
16,843 entries) with carbamidomethyl cysteine as a fixed modification and oxidation of methionine 
as a variable modification. Peptide mass tolerance was 10 ppm and fragment mass tolerance was 
0.01 Da. A total of 2,579 protein families were returned (raw data available by request to 
corresponding authors).  
 
Data was analysed independently by drug for both PSD95BP (Group 1 – VEH, Group 2 – KA, Group 3 
– VEH+PSD, Group 4 – KA+PSD) and 1400W (Group 1 – VEH, Group 2 – KA, Group 5 – VEH+1400W, 
Group 6 – KA+1400W), with statistical comparison between individual treatment groups in each 
analysis carried out using ANOVA within the Progenesis software. All proteins showing a statistically 
significant (p<0.05) change in normalised abundance between treatment groups were identified and 
reported on the basis of the number of peptides (including unique peptides) contributing to the 
analysis, p-value (uncorrected), false discovery rate (FDR) adjusted q-value, maximum fold change 
(Δ), and direction of effect. Lists of differentially expressed proteins were subject to Gene Ontology 
(GO) and KEGG pathway enrichment analysis using the R package ‘clusterProfiler’ (v3.10.1; Yu et al., 
2012) against the complete mouse annotation. KEGG pathway diagrams annotated with abundance 
data were generated using the KEGG pathview package (v1.22.30; Luo and Brouwer, 2013). 
 
3. Results 
3.1 Outcome of KA administration 
All KA-exposed animals experienced convulsive seizures (≥ stage 3) for >30 minutes during 2 hours of 
SE duration recorded from the time of onset of the first Stage 5 seizure to the termination with 
diazepam treatment. Seizure severity during SE was monitored visually in real-time and quantified as 
described previously (Beamer et al., 2012; Tse et al., 2014). There were no significant differences in 
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SE severity between animals that were allocated to Group 2, Group 4, and Group 6 (Figure 2). After 
termination of SE with diazepam, KA-treated animals and their matched controls were randomly 
allocated to treatment with either PSD95BP, 1400W or vehicle alone (as detailed in Figure 1). All 
interventions were applied after termination of behavioural SE to ensure that they did not modify 
the initial insult (i.e. severity of SE).  
 
All mice survived in this study due to the RLD method of SE induction by KA. However, as expected 
the animals lost bodyweight during the first 48 to 72 hours post-SE. Sterile dextrose saline 
supplement (1 ml, s.c.) twice daily for the first three days helped to regain the bodyweight. In the 7 
days between KA-induced SE and harvesting of tissue, animals were inspected visually on a twice-
daily basis as per standard husbandry practice. There were no overt signs of seizure activity in any of 
the animals during visual inspection, and no notable behavioural sequelae of KA and/or drug 
treatment. We were not able to incorporate continuous video-EEG monitoring in the current study 
due to the limited capacity (at that time) for contemporaneous recording. However, we have 
previously reported increased epileptiform spiking, numerous electrographic NCS, and occasional 
SRS during the first 7 days post-SE using the RLD method of KA administration to C57 mice 
(Puttachary et al., 2015).  
 
3.2 Effect of PSD95BP on the hippocampal proteome following KA-induced SE  
The effects of PSD95BP were investigated by the combined analysis of proteomic data from 4 groups 
of animals; Group 1 (VEH), Group 2 (KA), Group 3 (VEH+PSD) and Group 4 (KA+PSD). Of 2,579 
proteins detected in this study (see supplementary boxplots file), 175 individual proteins showed a 
significant change in abundance (p<0.05) as a result of intervention with PSD95BP following KA-
induced SE (supplementary table S1) but only 11 of those changes in abundance survived correction 
for multiple testing (q<0.05; Table 1).  
 
Seven of those 11 proteins were derived from comparison of data from Group 1 (VEH) and Group 2 
(KA) and were accordingly considered reflective of the effects of KA alone (Table 1). In all seven 
cases, protein abundance was significantly higher in Group 2 (KA) than in Group 1 (VEH), suggesting 
increased expression as a result of KA-induced SE at 7 days prior to harvesting of tissue. Two of the 
seven proteins whose abundance was significantly elevated by KA had a fold-change (Δ) that 
exceeded 2.00; heat shock protein beta-1 (Hspb1/Hsp27; Δ=4.08, q=0.0132; Figure 3) and glial 
fibrillary acidic protein (Gfap/GFAP; Δ=2.61, q=0.0132; Figure 3).  
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The remaining four proteins that showed a statistically significant alteration in abundance were 
related to PSD95BP treatment (Table 1). In three of four, abundance was highest in Group 2 (KA) and 
lowest in Group 3 (VEH+PSD), suggesting that treatment with PSD95BP alone reduced the expression 
of a protein that was otherwise elevated by KA-induced SE. Of those three, the greatest change in 
abundance was seen with CD44 antigen (Δ=4.94, q=0.0132; Figure 3). There was also a statistically 
significant change in the abundance of secretogranin (Δ=2.06, q=0.0351; Figure 3), with lowest 
abundance in Group 1 (VEH) and highest in Group 4 (KA+PSD). 
 
3.3 Effect of 1400W on the hippocampal proteome following KA-induced SE  
The effects of 1400W were investigated by the combined analysis of proteomic data from 4 groups 
of animals; Group 1 (VEH), Group 2 (KA), Group 5 (VEH+1400W) and Group 6 (KA+1400W). Of 2,579 
proteins detected in this study (see supplementary boxplots file), 168 individual proteins showed a 
significant change in abundance (p<0.05) as a result of intervention with 1400W following KA-
induced SE (supplementary table S2) but only 12 of those changes in abundance survived correction 
for multiple testing (q<0.05; Table 2).  
 
Five of those 12 proteins were derived from comparison of data from Group 1 (VEH) and Group 2 
(KA) and were again considered reflective of the effects of KA alone (Table 2). In all five cases, 
protein abundance was significantly higher in Group 2 (KA) than in Group 1 (VEH), suggesting 
increased expression as a result of KA-induced SE at 7 days prior to harvesting of tissue. Just one of 
the five proteins whose abundance was significantly elevated by KA had a fold-change that exceeded 
2.00; GFAP (Δ=2.61, q=0.0062; Figure 3).  
 
The remaining seven proteins that showed a statistically significant alteration in abundance were 
related to 1400W treatment (Table 2). Three of those showed highest abundance in Group 6 
(KA+1400W) and lowest in Group 1 (VEH), suggesting a combined action of KA-induced SE and 
1400W on protein expression, the most notable of which was a 4.61-fold increase in abundance of 
Hsp27 (q=0.011; Figure 3). Two proteins showed highest abundance in KA-treated mice (Group 2) 
and lowest in those treated with 1400W alone (Group 4), suggesting a suppressive action of the drug 
on the expression of a protein that was otherwise elevated by KA-induced SE; this was exemplified 
by CD44 antigen (Δ=3.92, q=0.0062; Figure 3). Finally, there were two proteins that showed modest 
(<1.5) but nonetheless significant fold-changes in abundance; Src substrate cortactin (q=0.0088; 
Figure 3), which was highest in Group 1 (VEH) and lowest in Group 6 (KA+1400W), and cytosolic 10-
12 
 
formyltetrahydrofolate dehydrogenase (Aldh1L1/AL1L1, q=0.0139; Figure 3), which was highest in 
Group 6 (KA+1400W) and lowest in Group 4 (VEH+1400W).   
 
3.4 Pathway analysis 
Individual proteins whose abundance was significantly (ANOVA p<0.05) altered in the PSD95BP 
analysis (supplementary table S1) and 1400W analysis (supplementary table S2) were subjected to 
gene ontology (GO) and KEGG pathway enrichment analyses against the complete mouse 
annotation. The most enriched GO terms, based on a hypergeometric distribution, amongst 
differentially abundant proteins in the PSD95BP dataset included those related to ‘neurotrophin 
binding’, ‘glutamate receptor binding’, ‘ion channel binding’, ‘translation initiation factor activity’, 
‘Rac GTPase binding’ and ‘protein kinase C binding’ (Figure 4A). KEGG pathway analysis on the 
PSD95BP dataset revealed ‘glutamatergic synapse’ and ‘butanoate metabolism’ to be the most 
enriched pathways (Figure 4B). Enriched GO terms amongst differentially abundant proteins in the 
1400W dataset included those related to ‘protein kinase C binding’, ‘actin/cytoskeletal binding’, 
‘extracellular matrix’, ‘amyloid-beta binding’, ‘ligase activity’, ‘phosphoprotein binding’, ‘coenzyme 
binding’, ‘cell adhesion molecule binding’ and ‘laminin binding’ (Figure 4A). KEGG pathway analysis 
on the 1400W datatset again revealed terms relating to ‘glutamatergic synapse’ as the most 
prominent, but also terms linked to ‘long-term depression’ and ‘extra-cellular matrix interactions’ 
(Figure 4B). Full lists of significantly enriched GO terms and KEGG pathways and their associated 
proteins are provided as supplementary tables 3 and 4. Visualisations of ‘glutamatergic synapse’ 
pathways for  PSD95BP and 1400W generated in the KEGG pathview package and annotated with 
corresponding protein abundance data are additionally provided in supplementary figures S1 
(PSD95BP) and S2 (1400W). 
 
3.5 Box-and-Whisker plots for all proteins 
A comprehensive supplementary data for all 2,579 proteins are included as Supplementary figure S3.  
 
4. Discussion 
Previous studies have provided important insights into the underlying cellular and molecular 
processes of epileptogenesis, highlighting neuroinflammation, the innate immune response, 
microglial activation, synaptic reorganisation and oxidative stress as key mechanisms in this regard 
(Liu et al., 2008; Li et al., 2010; Bitsika et al., 2016; Walker et al., 2016; Keck et al., 2017; Marques-
Carneiro et al., 2017; Keck et al., 2018). Many of these observations are unsurprising, given the 
burgeoning knowledge base surrounding the mechanisms and pathways believed to contribute to 
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the development of epilepsy (Pitkänen et al., 2015; Aronica et al., 2017; Becker, 2018; Godale and 
Danzer, 2018; Lukawski et al., 2018). Our experimental design is novel with respect to the choice of 
two putative anti-epileptogenic agents, i.e. PSD95BP (Tat-NR2B9c) that targets neurons and 1400W 
that targets the glial source of NO. This approach not only allowed an assessment of their molecular 
effects in normal brain but also an opportunity to explore their effects during the epileptogenic 
period. 
 
The KA mouse model of epileptogenesis is widely employed in experimental epilepsy research. We 
have used a repeated, low dose approach to the administration of KA that successfully resulted in 
sustained SE in all exposed animals, as described in our previous work (Tse et al., 2014; Puttachary et 
al., 2015). There were no significant differences in the severity of the initial SE in any of the relevant 
treatment groups, limiting the impact of insult heterogeneity on subsequent protein expression, and 
interventions (i.e. PSD95BP and 1400W) were administered at least one hour after the termination 
of SE to avoid the possibility of insult modification. Analysis of isolated hippocampal tissue at 7 days 
post-SE using a label-free proteomics approach detected a total of 2,579 unique proteins. Initial 
statistical analysis, stratified by drug treatment, identified approximately 170 proteins in each 
dataset whose abundance was significantly altered (ANOVA p<0.05). However, following appropriate 
correction for multiple testing, only a handful of proteins remained (tables 1 and 2). Of those, 
several were common to both datasets and had lowest abundance in vehicle-treated animals (Group 
1) and highest in the KA group (Group 2). They were accordingly considered to reflect the impact of 
KA-induced SE rather than intervention with either PSD95BP or 1400W. Those proteins included 
complement C1q subcomponent subunit B (C1qB), GFAP, and galectin-1, all of which have previously 
been implicated in epileptogenesis (Bischoff et al., 2012; Schartz et al., 2018).  
 
There is very recent evidence suggesting that C1q activation in microglia is an important mediator of 
neuroinflammation and epileptogenesis (Schartz et al., 2018). C1q proteins expressed during 
epileptogenesis also serve as extracellular organizers, responsible for recruitment and clustering of 
functional KA receptors on the postsynaptic membrane in hippocampal pyramidal neurons (Matsuda 
et al., 2016), suggesting a role in the perpetuation of SRS and the possibility that they might be 
viable targets for antiepileptogenic drug development. However, it should also be noted that C1q 
knockout mice develop epilepsy as a result of enhanced synaptic connectivity (Chu et al., 2010), 
implying that functional C1q proteins are required for effective synaptic pruning during development 
to establish normal connectivity (Ma et al., 2013). As with C1qB, an increase in the abundance of 
GFAP is consistent with the activation of astrocytes and microglial cells that is routinely observed 
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following brain insults (Ghirnikar et al., 1998). This finding lends further weight to the importance of 
glial cells in the early stages of epileptogenesis, by virtue of their role in neuroinflammation 
(Puttachary et al., 2016b; Terrone et al., 2017; Walker et al., 2017; Sharma et al., 2018a). It also 
serves to validate our experimental paradigm, as a lack of change in GFAP expression might have 
questioned the robustness of our model and/or the sensitivity of the data analysis. Less is known 
about the role of galectin-1 in epileptogenesis but there is some evidence that it can regulate 
neuronal cell death in the pilocarpine model of epilepsy (Bischoff et al., 2012). 
 
The majority of the statistically significant changes in individual protein abundance observed in this 
study were believed to be driven by KA-induced SE, rather than by treatment with either PSD95BP or 
1400W. This is perhaps not surprising, given the known neuropathological effects of KA exposure 
(Benkovic et al., 2006; Puttachary et al., 2016a). Nevertheless, analysis of the raw Progenesis output, 
as reported in tables 1 and 2, did identify a number of instances where changes in protein 
abundance were associated with drug treatment groups in one or both datasets.  
 
The two proteins with the greatest fold-changes in abundance were Hsp27 and CD44 antigen. The 
abundance of Hsp27 was highest in Group 6 animals (KA+1400W) and lowest in Group 1 (VEH), 
perhaps suggestive of an endogenous protective effect against the KA insult that is somehow 
augmented in the presence of iNOS inhibition. Hsp27 is considered to be a protector of cells and 
sub-cellular organelles, including mitochondria, and its expression is known to be induced under 
various pathological conditions (Franklin et al., 2005). Transgenic mice that overexpress Hsp27 are 
known to be resistant to KA-induced neurodegeneration suggesting its neuroprotective effects 
(Akbar et al., 2003). However, interestingly, it is also considered as a reliable marker of SE severity in 
the pilocarpine epilepsy model (Kirschstein et al., 2012), and is significantly up-regulated in resected 
neocortex from people with drug resistant epilepsy (Bidmon et al., 2004). CD44 antigen is cell 
surface glycoprotein that is traditionally considered to promote cell-cell interactions and cell 
migration and adhesion (Puré and Cuff, 2001). Recent evidence suggests that this role extends to 
maintenance of the structural and functional plasticity of dendritic spines (Roszkowska et al., 2016). 
The robust change in abundance of CD44 antigen, which was significantly elevated in Group 2 (KA) 
animals compared to drug treatment groups (Group 3, VEH+PSD; Group 5, VEH+1400W), suggests 
either the involvement of the innate immune response (mediated by T-cell migration) or an ongoing 
synaptic re-organization in the aftermath of KA-induced SE, both of which are plausible. 
Interestingly, an upregulation of hippocampal CD44 antigen has been also reported at 2 and 10 days 
post-SE in a rat model of epilepsy (Keck et al., 2018). 
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Other proteins that showed statistically significant changes in abundance associated with drug 
treatment included moesin, vimentin, Src substrate cortactin and secretogranin-2. Again, there is 
evidence to support a role for each of these proteins in epileptogenesis. Moesin has previously 
shown differential expression in sclerotic vs non-sclerotic human hippocampi from epilepsy patients 
(Lee et al., 2007) and up-regulation in epilepsy-associated glioneuronal lesions (Majores et al., 2005). 
Likewise, vimentin, an intermediate filament protein that co-localises with GFAP in reactive 
astrocytes (Sancho-Tello et al., 2005), is elevated in seizures associated with angiocentric glioma (Ni 
et al., 2015) and is also considered to be a marker of the astrogliosis seen in tuberous sclerosis 
(Sosunov et al., 2008). A change in abundance of Src substrate cortactin is consistent with the 
involvement of Src kinases and neuroinflammation in epileptogenesis, which we have demonstrated 
previously (Sharma et al., 2018), while secretogranin-2 is up-regulated following experimental 
seizures, particularly with KA, in a distinctive cell-type and species specific manner (Mahata et al., 
1992; Kandlhofer et al., 2000; Marti et al., 2002). 
 
All of the changes observed in individual protein abundance (i.e. C1q, GFAP, Hsp27, CD44 antigen, 
etc.) in this study were related to the processes of neuroinflammation and the activation of glial cells 
and the innate immune response, which served to confirm much of what is currently understood 
about the events underlying epileptogenesis. Interestingly, however, pathway analysis instead 
identified glutamate receptor binding, protein kinase C binding, cytoskeletal aspects and 
extracellular matrix interactions as the most significantly enriched GO terms and the glutamatergic 
synapse as the most enriched pathway. Accordingly, one might speculate that the individual protein 
changes reflected the dominant effect of KA-induced seizures, while the functional analysis, based 
on an unbiased, label-free proteomics analysis, was more sensitive to the pharmacology of the drugs 
employed in this study, both of which are known to target the glutamatergic synapse. 
 
This study has afforded an opportunity to identify proteins whose abundance is changed following 
KA-induced SE, and also following treatment with both PSD95BP and 1400W. Part of the rationale 
for this study was also to explore how those drugs might interfere with, and perhaps protect against, 
the epileptogenic process initiated by KA. That aim was predicated on two important assumptions; 
firstly that KA exposure is epileptogenic in the animals employed in this study, and that PSD95BP and 
1400W have antiepileptogenic properties. Our previous work supports the development of NCS and 
occasional SRS in the C57BL/6J mouse following KA-induced SE (Puttachary et al., 2015), but we did 
not specifically observe spontaneous seizures in the current 7 days post-SE study. Likewise, there is 
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existing evidence that PSD95BP and 1400W have disease-modifying properties in epilepsy models 
(Dykstra et al., 2009; Puttachary et al., 2016a; Putra et al., 2019) but, in the absence of overt 
epileptogenesis in the current study, it is not possible to prove that these drugs were 
antiepileptogenic on this occasion.  
 
Few studies have explored the proteomic signature of epileptogenesis to date (Liu et al., 2008; Li et 
al., 2010; Bitsika et al., 2016; Walker et al., 2016; Keck et al., 2017; Marques-Carneiro et al., 2017; 
Keck et al., 2018), all of which have been relatively small scale investigations involving small numbers 
of animals. In this respect, the current study is no different. Nevertheless, we have highlighted 
several key proteins that are seemingly perturbed by the process of epileptogenesis. Some of those 
proteins are already well-recognised (i.e. GFAP, C1q), whereas others (i.e. Hsp27, CD44 antigen) 
have not been widely reported previously in epilepsy models. Most are involved in 
neuroinflammation, which is widely believed to underlie the development of epilepsy, and the net 
effect of those changes in protein abundance appears to map to the glutamatergic synapse, which is 
the target of the experimental therapeutics used in this study. Our observations clearly require 
validation in a larger-scale investigation, with candidate proteins explored in more detail. This is only 
an exploratory study in males but more research is needed including in females. 
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Legends to figures 
 
Figure 1: Schematic representation of the experimental design (see text for full description). Data 
analysis was performed on PSD95BP (blue annotation) and 1400W (red annotation) datasets 
independently, albeit with common controls (i.e. Group 1 and Group 2). 
Figure 2: Comparison of the severity of status epilepticus (SE) between the treatment groups. 
Data is reported for those groups that received kainic acid (i.e. Group 2 (KA), Group 4 (KA+PSD) 
and Group 6 (KA+1400W)) and reflects the total time (in minutes) spent in convulsive seizures 
(CS; ≥ Stage 3) during a 2 hour period of SE. Data is illustrated as scatterplots, showing results 
from individual animals, and is also illustrated as the mean (± standard deviation) duration in 
each treatment group. There was no statistically significant difference in the duration of CS 
between groups (ns). 
Figure 3: Changes in the abundance of selected representative proteins (Hspb1 = heat shock 
protein beta-1; Gfap = glial fibrillary acidic protein; cd44 = CD44 antigen; Scg2 = secretogranin-2; 
Cttn = Src substrate cortactin; Aldh1|1 = cytosolic 10-formyltetrahydrofolate dehydrogenase). 
Protein abundance is expressed relative to control (Group 1; VEH) and illustrated in the form of 
box-and-whisker plots, showing median, inter-quartile range and minimum/maximum values. See 
text for full description. 
Figure 4: Pathway analysis of PSD95BP and 1400W datasets. GO enrichment analysis was performed 
using the “compareCluster” function in the R/Bioconductor package ‘clusterProfiler’. All proteins 
identified as showing a significant change in abundance in the PSD95BP or 1400W proteomes were 
loaded simultaneously in groups and either (A) statistically over-represented GO terms 
(hypergeometric test, p-value cutoff, p = 0.05, with Benjamini-Hochberg correction for multiple 
testing) or (B) KEGG pathway terms (p=value cutoff, p = 0.05, with Bonferroni correction for multiple 
testing) determined for each protein set. The most over-represented GO/KEGG terms are illustrated 
as dotplots, with gene ratio denoted by size and significant denoted by colour. 
 
Legends to tables. 
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Table 1. Data is derived from analysis of four treatment groups (n=4 per group); vehicle alone (VEH; 
Group 1), kainic acid alone (KA; Group 2), vehicle plus PSD95BP (VEH+PSD: Group 3) and kainic acid 
plus PSD95BP (KA+PSD; Group 4). Only those proteins with statistically significant (q<0.05) changes in 
normalised abundance after correction for multiple testing are reported. Data are ranked by q-value, 
low to high. Descriptors: accession = protein accession ID; peptides = total number of peptides 
contributing to analysis; unique = number of unique peptides contributing to analysis; p-value = 
ANOVA p-value, uncorrected; q-value = false discovery rate (FDR) corrected p-value; fold change = 
relative increase in mean normalised abundance comparing high group versus low group; high group 
= comparator group with highest mean normalised protein abundance; low group = comparator group 
with lowest mean normalised protein abundance; description = recognised protein name. 
 
Table 2. Data is derived from analysis of four treatment groups (n=4 per group); vehicle alone (VEH; 
Group 1), kainic acid alone (KA; Group 2), vehicle plus 1400W (VEH+1400W: Group 5) and kainic acid 
plus 1400W (KA+1400W; Group 6). Only those proteins with statistically significant (q<0.05) changes 
in normalised abundance after correction for multiple testing are reported. Data are ranked by q-
value, low to high. Descriptors: accession = protein accession ID; peptides = total number of peptides 
contributing to analysis; unique = number of unique peptides contributing to analysis; p-value = 
ANOVA p-value, uncorrected; q-value = false discovery rate (FDR) corrected p-value; fold change = 
relative increase in mean normalised abundance comparing high group versus low group; high group 
= comparator group with highest mean normalised protein abundance; low group = comparator group 
with lowest mean normalised protein abundance; description = recognised protein name. 
Legends to supplementary figures 
S1. Visualisations of ‘glutamatergic synapse’ pathways for PSD95BP generated in the KEGG pathview 
package and annotated with corresponding protein abundance data are illustrated. 
 
S1. Visualisations of ‘glutamatergic synapse’ pathways for 1400W generated in the KEGG pathview 
package and annotated with corresponding protein abundance data are illustrated. 
 
S3. A comprehensive supplementary data for all proteins are included as Box-and-Whisker plots. The 
horizontal dashed line in all graphs represents the value of 1 and the rest of the data in each graph 
represents normalized ratios of all other abundances of each replicate against Group 1 (Control).  
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Legends to supplementary tables 
 
Table S1. Data is derived from analysis of four treatment groups (n=4 per group); vehicle alone (VEH; 
Group 1), kainic acid alone (KA; Group 2), vehicle plus PSD95BP (VEH+PSD: Group 3) and kainic acid 
plus PSD95BP (KA+PSD; Group 4). All proteins (n=175) with statistically significant (p<0.05) changes in 
normalised abundance prior to correction for multiple testing are reported. Data are ranked by p-
value, low to high. Descriptors: accession = protein accession ID; peptides = total number of peptides 
contributing to analysis; unique = number of unique peptides contributing to analysis; p-value = 
ANOVA p-value, uncorrected; q-value = false discovery rate (FDR) corrected p-value; fold change = 
relative increase in mean normalised abundance comparing high group versus low group; high group 
= comparator group with highest mean normalised protein abundance; low group = comparator group 
with lowest mean normalised protein abundance; description = recognised protein name. 
Table S2. Data is derived from analysis of four treatment groups (n=4 per group); vehicle alone (VEH; 
Group 1), kainic acid alone (KA; Group 2), vehicle plus 1400W (VEH+1400W: Group 4) and kainic acid 
plus 1400W (KA+1400W; Group 6). All proteins (n=168) with statistically significant (p<0.05) changes 
in normalised abundance prior to correction for multiple testing are reported. Data are ranked by p-
value, low to high. Descriptors: accession = protein accession ID; peptides = total number of peptides 
contributing to analysis; unique = number of unique peptides contributing to analysis; p-value = 
ANOVA p-value, uncorrected; q-value = false discovery rate (FDR) corrected p-value; fold change = 
relative increase in mean normalised abundance comparing high group versus low group; high group 
= comparator group with highest mean normalised protein abundance; low group = comparator 
group with lowest mean normalised protein abundance; description = recognised protein name. 
Table S3. Enriched gene ontology (GO) terms in PSD95BP and 1400W analyses, as visually depicted 
in Figure 4A of manuscript. Lists of differentially expressed proteins (tables S1 and S2 for PSD95BP 
and 1400W, respectively) were subject to GO enrichment analysis using the R package 
‘clusterProfiler’ (v3.10.1) against the complete universe mouse annotation (Yu et al., 2012). 
Table S4: Enriched KEGG pathways in PSD95BP and 1400W analyses, as visually depicted in Figure 4B 
of manuscript. Lists of differentially expressed proteins (tables S1 and S2 for PSD95BP and 1400W, 
respectively) were subject to KEGG enrichment analysis using the R package ‘clusterProfiler’ 
(v3.10.1) against the complete universe mouse annotation (Yu et al., 2012). 
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